Borean Pharma receives Notice of Allowance of HIV drug patent by U.S. Patent & Trademark Office
Borean Pharma, ApS announced that it has received a Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) in connection with Borean's patent application for Human immunodeficiency Virus (HIV) fusion inhibitors for treating AIDS. The USPTO has stated that it intends to grant patent protection which covers six proprietary drug candidates capable of inhibiting HIV from infecting human cells. The patent is expected to expire in 2025.
Borean's HIV drug candidates are trimeric fusion proteins. These represent a next generation in HIV fusion inhibitors that are expected to combine greater patient safety and convenience with lower production and treatment costs.
"HIV remains one of the greatest challenges for medicine and this patent is therefore tremendously important to us," stated Dr. Johanna Holldack, CEO of Borean Pharma. "The acceptance of this patent is a significant milestone for Borean Pharma because it continues to solidify the positioning of our technologies and products."
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.